SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors react to a significant stock price drop following a quarterly earnings report that showed revenue missing estimates and a continued full-year loss. The community is heavily divided between bears pointing to the company's high debt levels and poor leadership performance, and bulls who are buying the dip in anticipation of future cost reductions and a long-awaited strategic partnership with POSCO.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors monitor the early-stage commercial rollout of Yartemlea following recent FDA approval, with the community closely tracking initial shipment metrics and potential milestone payments from the Novo Nordisk partnership. Discussions are heavily focused on the stock's volatility around option expirations and the anticipation of upcoming regulatory milestones in Europe as catalysts for a potential revaluation.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy (LNG) is experiencing significant market interest driven by its strategic role in global energy supply, including recent long-term contracts and sustained demand from both data centers and international markets. Investors are actively debating the stock's potential for S&P 500 inclusion and its long-term positioning as a leader in natural gas exports.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging on massive volume as traders bet on its role as a key natural gas supplier amidst European energy supply concerns. The community is actively discussing the stock's low float and the potential for a sustained short squeeze as geopolitical tensions fuel broader interest in energy security plays.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as investors anticipate the official launch of its Super App and analyze its expanding ecosystem partnerships, including integrations with major payment infrastructure providers. The community remains deeply divided, with some users highlighting its long-term utility and potential for institutional adoption, while skeptics point to price stagnation and supply concerns as reasons for caution.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) is facing significant downward pressure as investors re-evaluate positions following historic volatility in precious metals and broader market corrections. Community sentiment is deeply divided, with many traders debating whether current price action represents a healthy consolidation phase for a long-term bull market or a deeper structural trend reversal fueled by rising production costs and fluctuating bond yields.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility as investors weigh the stock's elevated valuation against long-term growth prospects in the AI server and custom chip sectors. The community is actively debating the stock's technical stability, with many closely watching pivotal support levels while analyzing how potential macro-driven headwinds and upcoming earnings could impact the company's shift toward high-margin AI inference workloads.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is trending as investors rally behind its decentralized AI infrastructure, with significant excitement building around its upcoming supply-halving event. The community is actively discussing its potential to serve as the foundational "Bitcoin of AI" while sharing strategies on subnet delegation and long-term accumulation.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending following positive FDA acceptance for a priority review of its supplemental New Drug Application, which aims to expand the use of Imcivree to children as young as two years old. The community is actively discussing the stock's clinical milestones and the potential for acquisition interest as the company pushes to solidify its leadership in treating rare genetic obesity.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is generating significant community buzz as investors digest a recent positive regulatory determination from NOAA, which confirmed the company's application for deep-sea mining is in substantial compliance. While community members debate the timing of final permits and the upcoming TMCR spin-off listing, the consensus among long-term holders remains focused on the company's strategic role in securing a China-independent supply chain for critical battery metals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Lisata...

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.read more...

Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs

(RTTNews) - Lisata Therapeutics Inc. (LSTA) announced that it has entered into a definitive agreement to be acquired by Kuva Labs Inc., a privately held company. Under the terms of the merger...

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Feb. 11, 2026 Insiders may stand to...

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA...

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable...

<ul class="summary-bullets"><li>Lisata and Kuva intend to enter into a definitive purchase agreement before Feb 27.</li><li>Under the deal, Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash.</li><li>Lisata shareholders will also be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.</li></ul>&nbsp;Shares of Lisata Therapeutics, Inc. (LSTA) soared 88% on Wednesday after the company said that it has a buyout offer from privately held Kuva Labs, Inc., valuing the company at up to $6/share.Lisata <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400">said</a> that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. In addition, Lisata shareholders will be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.The transaction has been approved by the board of both companies and Lisata and Kiuva intend to enter into a definitive purchase agreement before Feb 27, Lisata said.The $4 upfront purchase price represents a premium of about 85% from the stock’s closing price on Tuesday.<h2 class="st-heading-2">Lisata’s Pipeline</h2>Lisata’s lead product candidate Certepetide is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.In November 2024, Kuva had licensed Certepetide as a targeting and enhanced delivery agent to be used with its NanoMark platform technology. The NanoMark platform enables selective imaging of solid tumors with high contrast and spatial resolution, facilitating faster and more accurate diagnosis and treatment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LSTA stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that they are not selling their shares for below $8.<stembedurl>https://www.stocktwits.com/iNeedMillions/message/642431338</stembedurl>Another wondered if some other company would make a higher bid for Lisata.<stembedurl>https://www.stocktwits.com/Defen/message/642409160</stembedurl><a href="https://stocktwits.com/symbol/LSTA">LSTA stock</a> has gained 4% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-dismisses-rumors-of-1700-layoffs-at-german-gigafactory-report/cmUDDUFR4fV">Tesla Dismisses Rumors Of 1700 Layoffs At German Gigafactory: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Equity

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.


All-Cash Buyout Sparks Breakout Move in Biotech Name

Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Current Price	$5.01
Prev Close	$5.02
Open	$5.01
Dividend Yield	0.00%
50-Day Moving Average	$4.17
Beta	0.73
Avg. Volume	80,695.08
PE Ratio	-2.62

52-Week High	$5.07
52-Week Low	$1.81
Market Capitalization	$45.25M
EPS (Annual)	-$1.91
Price to Book	2.98
Revenue Per Employee	$8,095.24

LSTA
Lisata Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LSTA News

LSTALisata Therapeutics Inc